Neurosense Therapeutics LTD. (NRSNW) SEC Filings — 2025
22 SEC filings for Neurosense Therapeutics LTD. (NRSNW) in 2025.
Filings
- Neurosense Therapeutics LTD. 6-K Filing — 6-K · Dec 22, 2025
- NeuroSense Locks Alzheimer's Trial Data, Results Due Q1 2026 — 6-K · Dec 8, 2025
- Neurosense Therapeutics LTD. 6-K Filing — 6-K · Dec 4, 2025
- NeuroSense Gets FDA Green Light for ALS Phase 3 Trial — 6-K · Nov 24, 2025
- NeuroSense Therapeutics Files 6-K with Proxy Statement — 6-K · Nov 21, 2025
- NeuroSense's PrimeC Shows Alzheimer's Biomarker Reduction — 6-K · Oct 6, 2025
- NeuroSense Therapeutics Shareholders Approve All Proposed Resolutions — 6-K · Sep 25, 2025
- NeuroSense Alzheimer's Drug Shows Early Promise — 6-K · Sep 10, 2025
- NeuroSense Therapeutics Ltd. Private Placement — 6-K · Sep 4, 2025
- NeuroSense: PrimeC Shows 18-Month ALS Efficacy in New Analysis — 6-K · Sep 2, 2025
- NeuroSense Therapeutics Ltd. Files August 2025 6-K Report — 6-K · Aug 21, 2025
- NeuroSense ALS Drug PrimeC Shows Long-Term Safety in Phase 2a — 6-K · Aug 20, 2025
- NeuroSense Therapeutics Ltd. Files H1 2025 Business Update — 6-K · Aug 1, 2025
- NeuroSense Therapeutics Posts Q2 2025 Update Video — 6-K · Jul 10, 2025
- NeuroSense Completes Health Canada Meeting for ALS Drug — 6-K · Jun 26, 2025
- NeuroSense Completes PrimeC Manufacturing Scale-Up — 6-K · May 7, 2025
- NeuroSense Therapeutics Ltd. Updates Shareholders on Progress — 6-K · Apr 24, 2025
- NeuroSense Therapeutics Files 2024 Annual Report — 20-F · Apr 7, 2025
- NeuroSense Therapeutics Update on Pharma Deal Talks — 6-K · Mar 27, 2025
- NeuroSense Advances PrimeC for ALS in Canada — 6-K · Mar 19, 2025
- NeuroSense Therapeutics Reports New ALS Study Data — 6-K · Feb 19, 2025
- NeuroSense Therapeutics Regains Nasdaq Compliance — 6-K · Jan 6, 2025